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High-performance liquid chromatography (LC) and liquid chromatography/electrospray
ionization time-of-flight mass spectrometry (LC/ESI-MS) methods with various sample
preparation schemes were compared for their ability to identify and quantify glycoforms
in two different production lots of a recombinant monoclonal IgG1 antibody. IgG1s contain
a conserved N -glycosylation site in the fragment crystallizable (Fc) subunit. Six methods
were compared: (1) LC/ESI-MS analysis of intact IgG, (2) LC/ESI-MS analysis of the Fc
fragment produced by limited proteolysis with Lys-C, (3) LC/ESI-MS analysis of the IgG
heavy chain produced by reduction, (4) LC/ESI-MS analysis of Fc/2 fragment produced by
limited proteolysis and reduction, (5) LC/MS analysis of the glycosylated tryptic fragment
(293EEQYNSTYR301) using extracted ion chromatograms, and (6) normal phase HPLC
analysis of N -glycans cleaved from the IgG using PNGase F. The results suggest that MS
quantitation based on the analysis of Fc/2 (4) is accurate and gives results that are
comparable to normal phase HPLC analysis of N -glycans (6). (J Am Soc Mass Spectrom
2008, 19, 1643–1654) © 2008 Published by Elsevier Inc. on behalf of American Society for
Mass SpectrometryGlycosylation is an important determinant of thestability and biodisposition of protein drugs,including recombinant immunoglobulins (IgGs).
The challenges involved in characterizing glycosylation
in recombinant therapeutic proteins differ somewhat
from those associated with analyzing endogenous pro-
teins. Studies of glycosylation in human and animal
tissues are often focused on the general variation in
glycosylation patterns of a wide array of proteins, as in
proteomic experiments. In contrast, the analysis o f thera-
peutic proteins is focused on the complete characteriza-
tion and quantitation of glycosylation in the protein
drug product. Glycosylation in recombinant biothera-
peutic proteins varies widely with the cell culture
parameters [1, 2] and can influence efficacy, folding,
target binding, and pharmacokinetic properties [3–5].
Both the variability and physiological effects of gly-
cosylation make it important to accurately quantify
the carbohydrate structures found in biotherapeutic
proteins.
Immunoglobulin G molecules (IgGs), a class of im-
munoglobulins, have become attractive as therapeutic
proteins due to their high specificity and long circula-
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doi:10.1016/j.jasms.2008.07.004tion life [6]. An IgG1 molecule is a multi-chain, sym-
metric protein consisting of two identical fragment
antigen binding (Fab) arms, and a conserved fragment
crystallizable (Fc) stem connected through a flexible
hinge [7]. The Fab arms are composed of a light chain
connected through disulfide bonds to a portion of the
heavy chain (HC). The remaining portions of the two
HCs are linked to form the homodimeric Fc stem. The
Fc sequence is highly conserved in IgG molecules and
contains a single N-glycosylation site, Asn297 [7]. Gly-
cosylation in the Fc defines the structure of the CH2
domain and has been shown to be important for the
effector functions of the Fc [8]. Unlike most proteins in
which the carbohydrates are exposed, the carbohydrate
moiety in the Fc is buried between the two CH2
domains [9] where space constraints restrict the extent
of carbohydrate branching. Hence, the typical glyco-
form found in the Fc is the biantennary carbohydrate
structure [8]. The common variability in glycosylation
of IgG molecules is introduced by incomplete process-
ing of the galactose and fucose residues from the
biantennary oligosaccharide. In some cases, additional
heterogeneity is introduced by the presence of high
mannose glycoforms which are highly branched pre-
cursors of the biantennary carbohydrates [6]. While
IgGs are symmetric with regard to the amino acid
sequences of the light and heavy chains, glycosylation
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spectrometry can be used to identify glycoforms, as
each glycoform has a specific mass determined by its
composition. Recent advances in reversed-phase chro-
matography (rp-LC) and electrospray ionization mass
spectrometry (ESI-MS) have made it possible to analyze
glycoforms in samples of intact protein, as well as in
protein fragments and in peptides generated after com-
plete proteolysis with specific enzymes [11, 12]. Each of
these protein sample preparation methods offers poten-
tial advantages and disadvantages for glycoform anal-
ysis by MS, a topic that has been addressed in several
recent reviews [11]. Briefly, the analysis of glycosylation
in intact proteins offers the advantage of minimal
sample preparation and the ability to identify asymme-
try in glycosylation, but the wide natural isotopic
distribution of proteins may limit resolution [13]. In
addition, since IgGs are highly hydrophobic, solvents
such as isopropanol or n-propanol may be required for
their reversed-phase separation. Techniques based on
protein fragments or digests may offer higher resolu-
tion due to lower sample mass, but require more
extensive sample preparation (e.g., digestion, reduction,
alkylation) that may introduce artifacts. Furthermore,
though the quantitation of glycoforms using peak in-
tensities from deconvoluted ESI-TOF MS spectra has
been reported by our group [14] and others [15], con-
cerns remain regarding the accuracy and reproducibil-
ity of this method. An alternative approach involves
chromatographic analysis of glycans released from
the protein through enzymatic [16] (e.g., peptide N-
glycosidases) or chemical (e.g., -elimination) proce-
dures [11]. This “N-glycan release assay” is relatively
straightforward and well-established, but information
on the site of the protein–carbohydrate bond and po-
tential asymmetry in glycosylation of the two heavy
chains is lost with this approach. Sample preparation is
also more time-consuming for the N-glycan release
assay than for many of the LC/MS methods. Despite
these limitations, theN-glycan release assay is generally
considered the standard for glycoform analysis in the
biopharmaceutical industry.
The studies reported here compare six methods for
quantifying glycosylation in two production lots of an
IgG1: (1) LC/ESI-MS analysis of intact IgG (“intact IgG
method”), (2) LC/ESI-MS analysis of the Fc fragment
produced by limited proteolysis with Lys-C (“IgG Fc
method”), (3) LC/ESI-MS analysis of the IgG heavy
chain produced by reduction (“IgG HC method”), (4)
LC/ESI-MS analysis of Fc/2 fragment produced by
limited proteolysis and reduction (“IgG Fc/2 method”),
(5) LC/MS analysis of the glycosylated tryptic fragment
(293EEQYNSTYR301) using extracted ion chromato-
grams (“XIC method”), and (6) normal phase HPLC
analysis of the N-glycan cleaved from the IgG using
PNGase F (“N-glycan release assay”). The studies test
the hypothesis that the LC/MS-based methods (i.e.,
methods 1–5) provide identification and quantitation ofglycoforms that is equivalent to the N-glycan release
assay (i.e., method 6).
Materials and Methods
Materials
Trifluoroacetic acid (TFA), formic acid (FA) and guani-
dine hydrochloride (GdnHCl) were obtained from
Pierce (Rockford, IL). Tris(2-carboxyethyl) phosphine
hydrochloride (TCEP) and iodoacetamide (IAM) were
obtained from Sigma (St. Louis, MO). HPLC grade
water and acetonitrile (ACN) were obtained from VWR
International (West Chester, PA). Pepsin and trypsin
were obtained from Roche (Indianapolis, IN). The IgG
lots were produced and purified by using processes
proprietary to Amgen and kept frozen at 80 °C until
used. Endoprotease LysC was obtained from Roche
Diagnostics (Mannheim, Germany).
Sample Pretreatment
IgG samples were subjected to limited proteolysis and/or
reduction to produce the IgG Fc, IgG HC, and IgG Fc/2
fragments. Limited proteolysis was achieved by incubat-
ing the IgG samples with endoproteinase Lys-C [12] at a
protein/enzyme weight ratio of 400:1 in incubation buffer
(0.1M Tris-HCl, pH 8.0). The incubation was carried out at
37 °C for 3 min. The reaction was quenched by lowering
the pH to 4.5 with the addition of acetic acid. Reduction
was achieved by incubating 0.5 mL of IgG or an IgG Fc
fragment at a concentration of 2 mg/mL in denaturing
buffer (7.5 M GdnHCl, 120 mM sodium acetate, pH 5.0)
containing 5 mM TCEP, at 37 °C for 30 min.
Reversed-Phase Chromatography
Reversed-phase separation of intact IgG and IgG frag-
ments was carried out on an Agilent (Santa Clara, CA)
1100 HPLC system equipped with a Varian diphenyl 2 
150 mm column. Typically, 20 g of protein was injected
onto the column. The column was held at 95% Solvent A
(0.1% TFA in water) and 5% Solvent B (90% acetonitrile,
10% water, and 0.1% TFA in water) for 5 min followed by
a 2 min step gradient from 5% B to 35% B. Protein elution
was achievedwith a liner gradient from 35% B to 46% B in
40 min. The flow rate and column temperature were
maintained at 200 L/min and 75 °C, respectively,
throughout the run.
Mass Spectrometry
Mass spectrometric analysis was carried out on a Wa-
ters (Milford, MA) LCT premier equipped with an ESI
source operated in the W mode. The capillary and cone
voltages were set at 2500 and 80 V, respectively. The
desolvation gas and source temperatures were set at
350 °C and 80 °C, respectively. All the other voltages
were optimized to provide maximal signal intensity in
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Waters Masslynx MaxEnt 1 software to obtain the
deconvoluted mass. The instrument was calibrated in
the m/z range of 2500 to 4000 using multiply charged
ions of a standard antibody with a calculated MW value
of 148,251.2 Da.
Peptide Mapping
Reduced and alkylated IgG was buffer exchanged into
digestion buffer (1 M Tris, 1 M urea, and 20 mM
hydroxylamine at pH 7.0) at a protein concentration of
1 mg/mL using a NAP-5 column (Amersham Bio-
science, Uppsala, Sweden) following the procedure
described by the manufacturer. Trypsin digestion was
carried out by incubating 1 mg/mL of sample (in
digestion buffer) with 20 g of trypsin at 37 °C for 4 h,
followed by a second addition of 20 g of trypsin. The
mixture was allowed to incubate at 37 °C for 4 addi-
tional hours. The resulting tryptic peptides were sepa-
rated using a Waters Atlantis column, 2.0 mm  250
mm. Approximately 20 g of the digested material was
injected on the column. Elution was achieved using a
linear gradient from 100% Buffer A (0.1%FA) to 50%
Buffer A and 50% Buffer B (90% acetonitrile 0.085% FA)
in 170 min. The flow rate was maintained at 0.2 mL/
min and the column temperature was held at 50 °C.
N-Glycan Release Assay
The antibody samples were first diluted to 1 mg/mL
in digestion buffer provided with the Prozyme kit
(San Leandro, CA) and deglycosylated by addition of
PNGase F (Sigma St Louis, MO) at a weight ratio of
1:100 (PNGase F:antibody) followed by incubation at
37 °C for 24 h. The cleaved glycoforms were then
purified with a Glycoclean R cartridge from Prozyme
(San Leandro, CA) using the procedure described by
the manufacturer. The purified glycoforms were then
labeled with 2-aminobenzamide following the protocol
in the Prozyme labeling kit. Normal phase chromatog-
raphy was used to separate the labeled carbohydrates.
The separation was performed on an Agilent 1100
system equipped with an Amide-80, 4.6 mm 250 mm,
5 mm pore size column from Tosoh Biosciences (Grove
City, OH) and a fluorescence detector with the excita-
tion wavelength set at 330 nm and the emission wave
length set at 420 nm. Buffer A was 50 mM ammonium
formate (pH 4.4) and Buffer B was acetonitrile. The
gradient employed was 20% to 53% Buffer A over 132
min at 0.4 mL/min, then 53% to 100% Buffer A over 5
min at 0.4 mL/min followed by 100% Buffer A for 5 min
at 1 mL/min and re-equilibration in starting conditions
for 5 min at 0.4 mL/min.
Statistical Analysis
Results of the LC/MS based assays were compared
quantitatively with the standard N-glycan release assayusing a paired t-test,   0.05. The intact IgG and HC
assays were excluded from this comparison because
these assays detect paired glycoforms on dimeric pro-
teins, and so cannot be compared quantitatively with
the results of the N-glycan release assay.
Results
LC/MS Analysis of Intact IgG Molecules
Recent advances in rp-LC and ESI-MS have made
LC/MS analysis of intact IgGs routine [12, 13]. The
diphenyl column used in this study allows IgG separa-
tion with acetonitrile and has been shown previously to
resolve site-specific modifications in IgGs [17, 18]. ESI is
the preferred mode of ionization for the analysis of IgG
molecules as it produces a multiply charged envelope
in the m/z range of 2000 to 4000 that can be deconvo-
luted to obtain the nominal mass. A major constraint in
the MS analysis of large proteins is their wide, natural
isotopic distribution [13]. Since the full maximum at
half width (FMHW) of the isotopic distribution of an
IgG molecule is 40 Da, small mass changes introduced
by modifications such as oxidation (16 Da) are diffi-
cult to resolve for intact IgGs even with high-resolution
MS analysis. However, glycosylation variation in IgGs
is usually associated with larger mass changes, which
can be analyzed by standard time of flight instruments
with resolution between 5000 to 15,000 Da [14].
The deconvoluted mass spectra of two different
manufacturing lots (Lot a and Lot b) of a recombinant
monoclonal IgG1 analyzed with rp-LC /ESI-TOF are
shown in Figure 1. These spectra were obtained by
deconvoluting the raw m/z spectra (not shown). Both
lots of IgG showed multiple peaks, which can be
attributed to the galactose heterogeneity typically
found on the N-linked glycans present in the conserved
region of all IgG molecules. This typical N-glycan
profile described in earlier reports [19] is summarized
in Table 1. The (G0F)2peak from Figure 1 contains two
biantennary oligosaccharides, one on each heavy chain.
The G0F form has three mannose (hexose), four N-
acetylglucosamine residues, and a fucose residue. This
tri-mannosyl core structure (two N-acetylglucosamine
residues and the three mannose residues) is typically
conserved during the production of IgG molecules and,
hence, is unlikely to be the source of the identified
heterogeneity. The terminal galactose residues, how-
ever, show significant variability leading to the peaks
G0F/G1F, (G1F)2 etc., which are successively 162 Da
apart. In addition to these galactose variants, Man5/
Man5 and Man5/G0F structures were also observed.
Man5, Man6, Man7, Man8. and Man9 are high mannose
carbohydrates; these highly branched precursors of the
biantennary carbohydrates contain several branches of
mannose residues. The assignment of these peaks was
based on their deconvoluted mass. The observed mass
for the Man5/Man5 peak agrees well with its calculated
mass of 147787. However, the Man5/G0F peak was 9
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Man5/G0F peak is within 100 Da of the mass of G0/G0,
G0/G0F, and Man5/Man6 glycoforms. As described
earlier, the wide isotopic distribution for large proteins
makes it difficult to fully resolve these forms. The
incomplete resolution of the peaks could result in the
larger mass error observed for the Man5/G0F form.
The deconvoluted spectra of the IgG from Lots a and
b show some differences in their glycosylation profiles.
The IgG from Lot b had a greater extent of the terminal
galactose residues, which was evident from the higher
intensities of the G0F/G1F and (G1F)2 peaks. We have
shown previously that the intensities of the peaks from
the deconvoluted spectra can be accurately used for
quantitation of the hexose index (HexI), which is the
molar ratio of galactose residues per molecule of IgG
[14]. Additionally, the IgG from Lot b also showed
greater amounts of the high mannose containing peaks
than the IgG from Lot a.
These data indicate that LC/MS analysis of intact
IgG can be an adequate method for the high level
analysis of glycoforms on IgG molecules. Due to mini-
mal sample preparation involved, this method is adapt-
able to high throughput analysis. A critical limitation
Figure 1. Deconvoluted spectra of intact IgG
different lots (a) and (b) of the same recombina
various glycoforms identified based on the deco
2500 to 3700 was used with the followingMaxEn
minimum intensity ratio left and right, 50%; wi
number of iterations, 12.that becomes apparent in comparison with the othermethods is that low abundance glycoforms are not
detected, particularly many of the high mannose con-
taining glycoforms (see e.g., Figure 2). In addition,
individual glycoforms cannot be quantified, since the
method only provides the total masses of paired glyco-
forms. Because of these limitations, the results of the
intact IgG assay were excluded from further quantita-
tive comparisons (see Table 2). Analysis of intact IgG
could find application as a rapid screening method
during cell culture development.
LC/MS Analysis of IgG-Fc
The hinge region of an IgG is highly solvent exposed
and susceptible to proteolytic cleavage. Limited prote-
olysis of IgG molecules has been widely used to gener-
ate IgG subunits, which are generally more amenable to
LC/MS analysis than the intact molecule [20] [21].
Pepsin and papain have been classically used to clip
below and above the hinge region to generate F(ab)=2,
Fab, and Fc fragments. We have recently developed a
method for the limited proteolysis of human IgG1
mAbs using endoproteinase Lys-C [12]. Limited prote-
olysis with Lys-C causes a single cleavage at the C-
convoluted mass spectra generated from two
noclonal antibody. The peak labels refer to the
ted mass. For deconvolution, a m/z range from
ameters: mass range from 140,000 to 160,000 Da;
t half height for uniform Gaussian model, 1.5;. De
nt mo
nvolu
t1 par
dth aterminus of a lysine residue located in the hinge region
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proteolysis with Lys-C maintains the disulfide structure
Table 1. Structure, nomenclature and molecular weight of the
carbohydrate moieties typically observed in recombinant
monoclonal IgG molecules
Oligosaccharide structure Code
Mass
(Da)
G2F 1769.6
G1F 1607.5
G0F 1445.4
Man5 1217.2
Man6 1379.3
Man7 1541.4
Man8 1703.5
G0F-GlcNac 1242.2
G1F-GlcNac 1404.3
G0-GlcNac 1096.1
G2 1623.5
G1 1461.4
G0 1299.3of the Fc and Fab domains and, hence, allows thecharacterization of modifications in the disulfide archi-
tecture. In addition, limited proteolysis also conserves
the oligosaccharide pairing in the CH2 domain.
The deconvoluted spectra of the IgG-Fcs from the
two lots generated after limited proteolysis with Lys-C
are shown in Figure 2. IgG-Fc, with a mass of 50 kDa,
is roughly one-third the molecular weight of the intact
IgG molecule. Hence, IgG-Fc has a much smaller nor-
mal isotopic distribution with a FMHW of 15 Da,
which allows for improved isoform resolution. This is
evident from the spectra in Figure 2, which shows the
resolution of several additional peaks such as Man5/
Man6, Man5/Man7, G0/G0F, etc. The pairing of differ-
ent high mannose structures can lead to several isobaric
peaks. For example, Man6/Man6 and Man5/Man7
both have the same mass, but for simplicity only one
form (the most predominant) was used for labeling.
Overall, this method of glycoform analysis of IgG-Fc
yields at least 10 additional peaks compared with the
analysis of intact IgG. However, some forms of the
carbohydrate could not be fully resolved in these anal-
yses. The forms Man5/G0F and G-GlcNAc/G0F vary in
mass by only 25 Da and were not fully resolved. A
partial resolution of these forms was obtained in the
deconvoluted spectrum of Lot B from Figure 2.
Analysis of intact IgG and IgG-Fc allows the deter-
mination of oligosaccharide pairing, an effect described
previously by Masuda et al. [19]. Oligosaccharide pair-
ing can lead to a symmetric or asymmetric Fc portion.
Symmetric molecules have identical carbohydrates on
each chain while asymmetric molecules have different
carbohydrates on the two HCs. The study of pairing is
important as each of the carbohydrates on the HC can
have a cooperative and an additive effect on Fc function
[19]. In both lots, the symmetric Man5/Man5 form was
more abundant than the asymmetric Man5/G0F form.
Since the G0F form was significantly greater than the
Man5, a binomial distribution would lead to a greater
amount of the asymmetric Man5/G0F form than the
Man5/Man5 form. However, in both lots, the Man5/
Man5 form was greater in abundance than the Man5/
G0F, indicating a preferential pairing of the Man/
5Man5 form. This preferential pairing could be the
result of structural limitations imposed on the asym-
metric Man5/G0F form or could be caused by cell
culture parameters such as antibody titer, production
time, or other factors inherent to the cell line itself.
LC/MS analysis of the intact IgG and IgG-Fc is the only
method that allows detection of oligosaccharide pairing
in the IgG molecule.
While the detection of low abundance glycoforms is
improved by the analysis of IgG-Fc rather than intact
IgG, the method does not provide for the quantitation
of individual glycoforms but only glycoform pairs (see
below). The results of LC/MS analysis of IgG-Fc have
thus been excluded from the quantitative comparison
(see Table 2).
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Reduction of an IgG into individual heavy chains (HCs)
and light chains is another way to create IgG subunits
and is often performed before analysis. The IgG HC,
Figure 2. Deconvoluted spectra of intact IgG
from two different lots (a) and (b) of the same rec
to the various glycoforms identified based on th
from 1500 to 3000 was used with the following M
Da; minimum intensity ratio left and right, 50%;
number of iterations, 12.
Table 2. Quantitation of the IgG glycoforms with various analy
ion (XIC), and N-glycan release assay
Sugars
Reduced (HC) Limited and reduced
IgG A (%) IgG B (%) IgG A (%) IgG B
Man5 9.6  0.5 10.8  0.5 9.0  0.3 11.2 
G0F - GN ND ND 5.0  0.8 5.4 
G1F - GN ND ND ND N
G0 ND ND 2.0  0.02 N
Man6 ND ND 2.7  0.2 2.6 
Man6* ND ND ND N
G0F 55.8  1.0 44.1  0.3 39.7  0.6 36.0 
G1 ND ND 9.7  0.3 6.67 
Man7 ND ND 2.9  0.09 1.86 
G1F 31.0  1.4 38.0  0.4 22.6  0.1 26.4 
G1F* ND ND ND N
G2 ND ND 6.1  0.3 4.9 
Man8 ND ND 1.7  0.05 0.73 
G2F 3.6  0.5 7.0  0.4 3.4  0.1 4.21 ND  not detected, *  Isobaric form of that listed in the preceding row. Nwhich contains the carbohydrate is around 50 kDa,
similar in size to the IgG-Fc. Analysis of the HC is more
straightforward since reduction removes the complex-
ity caused by the pairing of oligosaccharides when the
econvoluted mass spectra of IgG-Fc generated
nant monoclonal antibody. The peak labels refer
onvoluted mass. For deconvolution, a m/z range
t1 parameters: mass range from 40,000 to 60,000
at half height for uniform Gaussian model, 0.8;
methods: reduced (HC), limited and reduced (Fc/2), extracted
) Extracted ion (XIC) N-glycan release
IgG A (%) IgG B (%) IgG A (%) IgG B (%)
5 17.2  0.6 18.1  1.4 11.0  0.5 12.9  0.5
7 4.0  0.2 6.2  0.4 6.4  0.2 6.0  0.2
ND ND 1.8  0.07 1.3  0.2
0.8  0.1 ND ND ND
1.0  0.2 1.3  0.2 2.7  0.2 3.0  0.09
ND ND 0.6  0.05 1.0  0.04
68.3  1.5 60.7  1.2 46.9  1.3 40.3  0.7
6 ND ND ND ND
7 ND ND 2.1  0.3 2.8  0.2
8.3  0.6 12.9  0.5 16.8  0.3 19.3  0.4
ND ND 6.4  0.2 7.4  0.4
ND ND ND ND
3 ND ND ND ND
2 0.3  0.06 0.7  0.05 3.5  0.2 4.7  0.5Fc. D
ombi
e dec
axEn
widthtical
(Fc/2
(%)
0.0
0.0
D
D
0.2
D
0.3
0.0
0.0
0.1
D
0.1
0.0
0.0 6 /– standard deviation.
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different analytes possible. For example, if five different
glycoforms may be covalently attached to the heavy
chains, the number of different masses expected for the
HC fragment is five. In samples containing the dimeric
heavy chain (i.e., IgG, IgG Fc), however, the number of
possible masses is 25 32, a consequence of the fact that
different glycoforms may be linked to each of the heavy
chains. Reduction of the IgG into monomeric HC frag-
ments does result in fewer peaks, as shown in the
deconvoluted spectra in Figure 3. The spectra of the HC
show the biantennary oligosaccharides G0F, G1F, and
G2F, along with smaller amounts of the high mannose
forms. The paired glycoforms detected in intact IgG and
IgG-Fc samples (e.g., Man5/Man5, G0F/G1F, Figures 1,
2) are absent, however, as expected. Since in the analy-
sis of IgG-HC the pairing effect is removed, the inten-
sity of peaks for the various carbohydrate structures can
be used to quantify the various glycoforms. The MaxEnt
algorithm used for generating the deconvoluted spectra
Figure 3. Deconvoluted spectra of intact IgG
(IgG-HC) generated from two different lots (a) an
The peak labels refer to the various glycoform
deconvolution, a m/z range from 1500 to 3000 wa
range from 40,000 to 60,000 Da; minimum inten
uniform Gaussian model, 0.8; number of iterations, 1preserves the intensity information from the raw spec-
tra, allowing accurate quantitation.
LC/MS Analysis of IgG-Fc/2
Fc/2 refers to the constant region of the single HC and
is produced after reduction of the Fc. Fc/2 is 25 kDa,
is half the size of the HC, and has a smaller normal
isotopic distribution that allows for greater resolution of
modifications. The deconvoluted spectra of Fc/2 from
the two different lots are shown in Figure 4. Compared
with the deconvoluted spectra of HC (Figure 3), the
Fc/2 spectra showed improved resolution for the vari-
ous glycoforms, which was clearly observed in peaks
such as Man5 and G0F-GlcNAc. Additional low inte-
nsity peaks such as G0 were more clearly visible in
the spectra for Fc/2. The improved detection of low
intensity peaks could be the result of improved signal to
noise of the more compact peaks in Fc/2. The higher
sensitivity led to the identification of a greater number
. Deconvoluted mass spectra of heavy chains
) of the same recombinant monoclonal antibody.
entified based on the deconvoluted mass. For
d with the following MaxEnt1 parameters: mass
atio left and right, 50%; width at half height forHC
d (b
s id
s use
sity r2.
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G0, G1, and G2 carbohydrates were not observed in the
intact IgG, IgG-Fc, or HC spectra, they were detected in
the Fc/2 spectra. Similar to the previous analyses, the
amount of the high mannose forms was higher in Lot b.
Glycoforms with a mass difference as low as 25 Da were
baseline-resolved, which subsequently allowed im-
proved quantitation of these forms. All the peak assign-
ments in the deconvoluted spectra were based on the
calculated mass with errors less than 200 parts per
million (ppm).
LC/MS Analysis After Trypsin Digestion
(XIC Method)
Tryptic peptide mapping is commonly used to deter-
mine chemical modifications and sequence variants in
proteins [22]. Peptide mapping relies on specific cleav-
age of the protein sequence with a proteolytic enzyme
such as trypsin, giving rise to a known set of peptides.
The subsequent LC/MS allows determination of site
specific modifications in proteins. Peptide mapping has
Figure 4. Deconvoluted spectra of intact Ig
generated from two different lots (a) and (b) of th
labels refer to the various glycoforms identified
a m/z range from 1500 to 3000 was used with t
20,000 to 40,000 Da; minimum intensity ratio le
Gaussian model, 0.5; number of iterations, 12.been widely used for the characterization of IgG mole-cules. Complete trypsin cleavage of IgG1 molecules
generates the peptide 293EEQYNSTYR301, which con-
tains the N-linked carbohydrate moiety on N297. Stan-
dard reversed-phase separation methods may not re-
solve the various glycoforms on the peptide. However,
each glycoform (apart from isobaric structures) can be
distinguished by its specific mass. The intensities spe-
cific to the glycoforms can be obtained from the total ion
chromatogram (TIC) by generating extracted ion chro-
matograms (XIC). XICs are generated by extracting the
ion signal for the mass of a particular peptide from the
total ion chromatogram acquired on the mass spectrom-
eter. This method allows the analysis of a specific
compound in a mixture of analytes. Figure 5 shows the
peptide maps (inlays) and XICs for the various glyco-
forms in the two lots. This method had a low sensitivity,
and only five glycoforms (Man5, Man6, G1F, G0F, and
G0F-GlcNAc) could be detected. XICs of other glyco-
forms, which were detected in the previous analyses,
did not show measurable peaks (not shown). A differ-
ence in retention of the glycoforms was observed, and
highly branched structures (high mannose) had a
/2. Deconvoluted mass spectra of IgG-Fc/2
e recombinant monoclonal antibody. The peak
on the deconvoluted mass. For deconvolution,
llowing MaxEnt1 parameters: mass range from
d right, 50%; width at half height for uniformG Fc
e sam
based
he fo
ft anshorter retention time than the biantennary structures.
1651J Am Soc Mass Spectrom 2008, 19, 1643–1654 QUANTITATION OF GLYCOSYLATION IN IgGs WITH TOFSimilarly, the size of the carbohydrate moiety also
affected their retention.
N-Glycan Release Assay
An N-glycan release assay is the most commonly used
method for the quantitation of glycoforms in IgG mol-
ecules and other glycoproteins. For this assay, the
N-linked carbohydrate is released from the protein with
PNGase F or other glycanases specific for N-linked
glycans. The released N-glycans are purified from the
protein and analyzed with normal-phase chromatogra-
phy [23], MALDI, or other techniques [24, 25]. In most
cases, the released oligosaccharides are derivatized
through their reactive reducing end before analysis.
Derivatization is used to introduce fluorescent tags,
which improve the normal-phase separation as well as
the sensitivity of detection [16]. The chromatograms of
PNGase F released oligosaccharides from the two lots,
derivatized with 2-aminobenzamide and separated
Figure 5. Extracted ion chromatograms (XIC) fo
two different lots (a) and (b) of the same recomb
The extracted ion chromatograms (XICs) from th
labels refer to XICs of the doubly charged ion fo
used to generate the XICs: G0F; 1318.3, G1F; 13
and Man6; 1285.7.with normal-phase chromatography, are shown in Fig-ure 6a. The glycoform profile shown in Figure 6a agrees
very well with that published by Hill et al. [16]. Addi-
tional online MS analysis was carried out to identify the
peaks separated by normal-phase chromatography
(Figure 6b). For simplicity, only the mass spectra for
G0F-GlcNAc, Man5, and G0F peaks are shown in Fig-
ure 6b. Similar mass spectra were obtained for other
peaks as well. In a previous study by Hill et al. [16],
retention of a standard dextran ladder and glucose unit
values for each oligosaccharide were used for assign-
ment of peaks from the normal-phase chromatogram.
According to that assignment, Man5 was reported to
elute just before the G0F peak, while the peak eluting
after G0F was assigned as Man6. However, our LC/MS
data clearly shows Man5 to elute after the G0F peak,
while the peak eluting before G0F was assigned as a
mixture of G0F-GlcNAc and G0 (Figure 6b). The MS
analysis allowed a more accurate identification leading
to reassignment of the high mannose peaks. The highly
branched nature of the high mannose oligosaccharides
various glycoforms. Peptide maps of IgGs from
t monoclonal antibody are shown in the inlays.
ptide maps of the two lots are shown. The peak
various glycoforms. The following masses were
G2F; 1480.5, G0F-GlcNAc; 1217.2, Man5; 1204.7r the
inan
e pe
r the
99.4,probably leads to a stronger interaction with the normal-
1652 SINHA ET AL. J Am Soc Mass Spectrom 2008, 19, 1643–1654phase column causing these forms to be retained more
than the corresponding biantennary structures with
higher glucose unit values. LC/MS analysis also al-lowed the identification of several new peaks such as
G0-GlcNAc and G0 which were detected but not as-
signed in the previous study by [16] (Figure 6a). In
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phase method could not fully resolve all the glyco-
forms. G0F-GlcNAc and G0, as well as Man5 and G1
were found to coelute. The lowMS signal for G1 (Figure
6b) may be due to ion suppression of the branched
Man5 carbohydrate. Since elution in normal-phase
chromatography is generally influenced by the amount
of carbohydrate, the G2 form would be expected to
coelute with the Man6 form. However, the spectra for
the Man6 form did not show the presence of the G2
form (data not shown). The coelution of these carbohy-
drate structures is a major limitation in quantitation
using the N-glycan release assay.
Quantitative Comparison of Assay Results
The quantitation of glycoforms by four different meth-
ods is summarized in Table 2. As noted in sections
above, LC/MS analysis of intact IgG and of IgG-Fc are
not included in the quantitative comparison because
these methods do not detect individual glycoforms but
only glycoform pairs. Table 2 summarizes the quantita-
tive analysis of glycosylation by the four methods that
detect monomeric (i.e., unpaired) glycoforms. The
methods differ in both the number of glycoforms de-
tected and in the quantitative distribution of the glyco-
forms. Note that in Table 2 the total percentages of all
glycoforms sum to 100% for each of the methods. This
introduces bias in quantitative comparison of methods
that detect different numbers of glycoforms. To allow
for more accurate comparison, percentages were
rescaled to include only the four glycoforms detected by
all four methods (i.e., Man5, G0F, G1F, G2F). In addi-
tion, isobaric forms that were resolved by the N-glycan
release assay (i.e., Man6 and Man6*, G1F and G1F*)
were pooled for this comparison.
The number of glycoforms detected by the reduced
(HC) and extracted ion (XIC) methods are less than by
the other two methods (Table 2). Low abundance gly-
coforms, accounting for less than 5% of the total, are
infrequently detected by the HC and XIC methods. For
example, with the exception of G2F, the HC method
does not detect any of the glycoforms that are at less
than 5% abundance by the N-glycan release assay.
While the XIC method detects some of these low
abundance glycoforms (e.g., Man6, G0), low abundance
forms with higher mass (e.g., G2) are not detected. In
contrast, the limited and reduced (Fc/2) assay detects
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Figure 6. N-glycan release assay of the two Ig
benzamide labeled carbohydrates from two d
monoclonal antibody. The peak labels refer to var
spectra of peaks from Figure 6(a). The ident
aminobenzamide labeled carbohydrates. Peaks l
sodium and sulfate adducts. The theoretical ma
carbohydrate structures are as follows: G0F; 1583
G1; 1599.5. The trace for the G1 peak was magni
signal of the Man5 peak.11 glycoforms for Lot A and 10 glycoforms for Lot B,
comparable with the 10 glycoforms detected for each
antibody by the N-glycan release assay (Table 2).
It can also be seen from Table 2 that for Man5, G1F,
and G2F, values obtained by the HC and XIC methods
differ significantly from those obtained by the N-glycan
release assay. The XIC results also differ significantly
from the N-glycan release assay for the most abundant
glycoform, G0F. In contrast, the results of the Fc/2
method are not significantly different from those of the
N-glycan release assay for any of the four major glyco-
forms. Thus, the Fc/2 assay provides results that are
comparable to the N-glycan release assay in both the
number of glycoforms detected and the quantitative
values.
Several reasons can be proposed for the quantitative
and qualitative differences among the four methods.
The poor ability of the HC method to detect glycoforms
and to provide quantitative agreement with the stan-
dard N-glycan release assay may reflect poor ionization
of the relatively large (50 kD) glycosylated HC mole-
cule. The XIC method may be susceptible to suppres-
sion of the glycopeptide signal due to the attached
carbohydrate for the relatively small peptide fragments
produced by digestion. The good agreement between
the Fc/2 assay and the standard N-glycan release assay
may be due in part to the improved ionization of this
glycosylated protein, intermediate in size (26 kD)
between the HC and XIC fragments.
While the N-glycan release assay is regarded as a
standard in monitoring IgG glycosylation, it is not
without limitations. Of the methods studied here, only
the N-glycan release assay could detect and resolve
isobaric glycoforms (i.e., Man6 and Man6*, G1F and
G1F*, Table 2). The N-glycan release assay also showed
high precision as reflected by the low standard devia-
tion. However, online mass spectrometric analysis
showed coelution of some of the carbohydrate struc-
tures during the N-glycan release assay, which greatly
restricts its ability to quantitate these glycoforms. In
particular, values for the Man5 and G0-GlcNAc re-
ported for the N-glycan release assay in Table 2 are not
accurate because these carbohydrate structures coelute
with the G0 and G1 forms, respectively, making their
quantitation suspect.
Overall, the quantitation obtained with the Fc/2
assay was comparable to that of the N-glycan release
assay and the small differences observed can be attrib-
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
ts. (a) Normal-phase chromatograms of amino-
nt lots (a) and (b) of the same recombinant
glycoforms identified based on the mass; (b)m/z
ion was based on the accurate mass of the
d with an asterisk and a plus symbol represent
 H) of the amino benzoic acid forms of the
0; 1437.4; G0F-GlcNAc; 1380.3 Man5; 1355.3 and
4 to enable display in the presence of a strong™™™
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iffere
ious
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ss (M
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1654 SINHA ET AL. J Am Soc Mass Spectrom 2008, 19, 1643–1654uted to coelution of certain forms during the N-glycan
release assay. A limitation of the Fc/2 assay, and of any
rpLC/MS approach, is that isobaric structures (i.e.,
Man6 and Man6*, G1F and G1F*) cannot be resolved
with this method. The Fc/2 and N-glycan release assays
thus are highly complementary and, when used to-
gether, are expected to provide complete characteriza-
tion of carbohydrates in therapeutic recombinant mono-
clonal IgG molecules.
Conclusions
The studies reported here highlight strengths and lim-
itations of LC/ESI-TOF MS assays for the identification
and quantitation of glycoforms in IgGs. ESI-TOF anal-
ysis of the intact IgG was able to adequately measure
the galactose variance in the biantennary N-glycan
structure, but could not resolve the heterogeneity
caused by high-mannose carbohydrates. ESI-TOF anal-
ysis of the IgG-Fc fragment generated after limited
proteolysis enabled detection of both biantennary and
high-mannose carbohydrates, and was effective in char-
acterizing oligosaccharide pairing caused by the com-
bination of glycans on the two IgG-Fc heavy chains.
Neither the intact IgG nor the IgG Fc analysis was
found to provide sufficient resolution for quantitation,
however. ESI-TOF analysis of the IgG-Fc/2 fragment
showed accurate quantitation of various biantennary
and high-mannose oligosaccharides, and was the most
effective of the MS based methods evaluated at identi-
fication and quantitation. Peptide mapping followed by
ESI-TOF MS analysis was not effective for absolute
quantitation, as the ionization of glycopeptides was
influenced by the size of the carbohydrate. Though
the N-glycan release assay showed high precision, the
normal-phase method used for the assay could not fully
resolve all the glycoforms. Collectively, the results
suggest that MS quantitation based on analysis of Fc/2
(reduced Fc) is accurate and gives results that are both
comparable and complementary to the more time-
consuming N-glycan release assay.
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